Kura Oncology, Inc. (NASDAQ:KURA) Shares Purchased by 1492 Capital Management LLC

1492 Capital Management LLC boosted its stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 367.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 342,598 shares of the company's stock after acquiring an additional 269,374 shares during the period. Kura Oncology comprises approximately 1.4% of 1492 Capital Management LLC's portfolio, making the stock its 27th largest position. 1492 Capital Management LLC owned approximately 0.44% of Kura Oncology worth $2,984,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its position in Kura Oncology by 11.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock worth $144,000 after acquiring an additional 1,750 shares during the period. Rhumbline Advisers grew its position in Kura Oncology by 2.0% in the 4th quarter. Rhumbline Advisers now owns 99,991 shares of the company's stock valued at $871,000 after buying an additional 1,923 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock valued at $430,000 after buying an additional 2,076 shares during the period. Teacher Retirement System of Texas raised its position in Kura Oncology by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock worth $120,000 after buying an additional 2,285 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Kura Oncology by 0.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company's stock worth $7,997,000 after acquiring an additional 3,092 shares during the period.

Insider Activity at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,729 shares of company stock valued at $92,307. Corporate insiders own 5.50% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on KURA. JMP Securities reaffirmed a "market outperform" rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. Cantor Fitzgerald upgraded shares of Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. BTIG Research lowered shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. HC Wainwright reiterated a "buy" rating and set a $40.00 price target on shares of Kura Oncology in a research report on Thursday, February 27th. Finally, UBS Group lowered their price target on Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Three research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $25.50.

Kura Oncology Stock Up 1.1 %

Shares of NASDAQ KURA traded up $0.07 on Wednesday, hitting $6.38. The company had a trading volume of 354,211 shares, compared to its average volume of 1,143,567. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $23.48. The firm has a market capitalization of $515.36 million, a P/E ratio of -2.70 and a beta of 0.83. The business has a 50 day moving average of $6.99 and a two-hundred day moving average of $10.23.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. As a group, equities research analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.